samedan logo
 
 
spacer
home > ict > autumn 2017 > perfect planning
PUBLICATIONS
International Clinical Trials

Perfect Planning

The cell and gene therapies being developed today have the potential to cure diseases. To make those treatments possible, another industry has to evolve: logistics. In the past two decades, gene-based clinical trials have increased by almost 500%. The global market for regenerative medicines – including cell therapies, gene/gene-modified cell therapy and tissue engineering – is poised to reach $67 billion in 2020.

While the majority of cell and gene therapies are still experimental – aimed at rare single-gene disorders – researchers hope to build on their successes to develop treatments for multi-gene disorders, including heart disease, hypertension, diabetes, arthritis and Alzheimer’s. This makes the success of clinical trials now vitally important to humanity. However, therein lies the challenge. Unlike traditional medicines, these therapies contain living cells or viral vectors that must be protected to ensure their survival and effectiveness.

Therapies that contain these materials are produced and packaged under strictly controlled conditions. They must be transported around the world and delivered on time at optimum temperature to ensure they arrive in perfect condition. This must be done regardless of weather, traffic, mechanical difficulties, staffing irregularities, customs regulations or processing delays.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lisa Vocat is Global Content Marketing Manager at World Courier, part of AmerisourceBergen’s global specialty logistics business. She is responsible for World Courier’s content marketing strategy and thought leadership development.
spacer
Lisa Vocat
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement